OAM
SEEL

Oxford Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Oxford Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4
Closed -$54K – 2007
2019
Q1 		$54K Buy
+4
New +$64.7K ﹤0.01% 1599
2018
Q1 		– Hold
0
– -$53K – 1934
2017
Q4 		– Hold
0
– – – 1555

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Oxford Asset Management's SEEL Position: Q2 2019 in Review

Oxford Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2019, closing a stake of 4 shares — an estimated $54K sold.

Oxford Asset Management first reported a position in SEEL in Q1 2019 and held it in 1 quarter. The position peaked at $54K in Q1 2019. 14 funds tracked by Wall St. Rank hold SEEL as of Q2 2019.

  • Oxford Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Oxford Asset Management sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $54K.
  • Oxford Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Oxford Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $54K in Q1 2019.
  • 14 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.